Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1991007175) USE OF OPTICALLY PURE S(-) ATENOLOL FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/007175 International Application No.: PCT/US1990/006824
Publication Date: 30.05.1991 International Filing Date: 21.11.1990
Chapter 2 Demand Filed: 20.06.1991
IPC:
A61K 31/165 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide
Applicants:
SEPRACOR, INC. [US/US]; 33 Locke Drive Marlborough, MA 01752, US
Inventors:
BARBERICH, Timothy, J.; US
BRATZLER, Robert, L.; US
YOUNG, James, W.; US
LOUIS, William, J.; AU
Agent:
GRANAHAN, Patricia ; Hamilton, Brook, Smith & Reynolds Two Militia Drive Lexington, MA 02173, US
BROOK, David, E.; Hamilton, Brook, Smith & Reynolds Two Militia Drive Lexington, MA 02173, US
Priority Data:
440,03621.11.1989US
Title (EN) USE OF OPTICALLY PURE S(-) ATENOLOL FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS
(FR) EMPLOI DE S(-) ATENOLOL OPTIQUEMENT PUR DANS LE TRAITEMENT DE TROUBLES CARDIOVASCULAIRES
Abstract:
(EN) Optically pure S(-) atenolol, which is substantially free of the R(+) enantiomer, is a potent beta-blocker for controlling heartbeat, relieving the symptoms of angina pectoris and reducing blood pressure in individuals. A method is disclosed utilizing the optically pure S(-) enantiomer of atenolol for treating cardiovascular disorders while reducing undesirable side effects associated with beta-blockers.
(FR) Le S(-) aténolol optiquement pur, lequel est exempt du R(+) énantiomère, constitue un agent bêta-bloquant puissant dans la régulation des pulsations cardiaques, soulageant les symptômes de l'angine de poitrine et réduisant la pression sanguine chez des individus. Un procédé est décrit, lequel utilise le S(-) énantiomère d'aténolol optiquement pur, afin de traiter des troubles cardiovasculaires, tout en réduisant les effets secondaires indésirables associés aux agents bêta-bloquants.
Designated States: AU, CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0519925JPH05503510CA2069404AU1991068933